Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV

Funded by the National Institute on Drug Abuse as a Center of Excellence

Learn about us
Center for Health Economics of Treatment for Substance Users Is Established at Weill Cornell Medical College Read more

This Issue Brief discusses the role of primary care teams in identifying illicit drug use disorders in their patients, the continuum of treatments that they can offer, and opportunities for successful collaboration and integration with specialists. The authors find opportunities exist for increased patient screening and delivering medication-assisted treatment as well as established models for […]

Read more

meisel-zack-200v

By Hoag Levins 36-Month Study to Focus on Opioid Risk Communications in Clinical Settings University of Pennsylvania Assistant Professor of Emergency Medicine and LDI Senior Fellow Zachary Meisel, MD, has received a $2.1 million funding award from the Patient-Centered Outcomes Research Institute (PCORI). The award will fund a 36-month comparative effectiveness study of enhanced opioid risk […]

Read the full story

Two weeks ago, the Department of Health and Human Services (DHHS) announced changes in buprenorphine treatment regulations that would allow certain licensed physicians to provide buprenorphine to up to 275 patients. This is an increase from the 100 patient limit set forth by the Office of National Drug Control Policy (ONDCP) Reauthorization Act of 2006. The […]

Read the blog post

Despite growing recognition that substance use disorder is a chronic disease, quality of life is rarely measured in substance use disorder treatment studies. With funding from the National Insitute on Drug Abuse (NIDA) R01DA033424, investigators measured the quality of life in prescription and injection opioid misuse using primary data from a survey of the US […]

Read more

Following approval by the US Food and Drug Administration (FDA), probuphine will become the latest medication-assisted treatment (MAT) option to treat opioid use disorders in the United States. Probuphine is a subdermal implant that consists of four one-inch rods that deliver a daily dose of 8 mg of buprenorphine, an opioid agonist that staves off […]

Read the blog post

Join Our Mailing List

EVENT


Treating Hepatitis C in Primary Care: Preliminary Results of a Budget Impact Analysis

Friday, September 9, 2016
1:15 pm — 2:15 pm
Karen E. Lasser, MD, MPH, Associate Professor of Medicine and Public Health
EVENT


AIDS Seminar: NYS Medicaid Reform: How Will Medicaid Transformation Affect Access & Quality to Care for Patients with HIV, HCV, and Drug Dependence?

Tuesday, September 13, 2016
10:30 am — 11:30 am
Andrew Cleek, PsyD & Boris Vilgorin — NYU Silver School of Social Work

Methodology

Experts in cost benefit, cost effectiveness, and budget impact analyses

Learn More Consultation Request

HCV and HIV

Experts in economic analysis of HCV and HIV and treatment among substance users

Learn More Researcher Services

Dissemination and Policy

Experts in disseminating health economic research among policy makers and the public

Learn More

Pilot Grant and Training

Supports new investigators and investigators new to health economic research in substance use disorders, HCV, and HIV

Learn More Pilot Grants

View Our Publications and Presentations